Stoke Therapeutics reported a dramatic financial turnaround for the nine months ended September 30, 2025 (9M 2025), achieving $51.0M Net Income on $183.0M Revenue, compared to a \(78.5M loss on \)13.9M revenue in 9M 2024. Diluted EPS for the 9-month period was \(0.85. However, the most recent quarter (Q3 2025) posted a **\)38.3M Net Loss**, as operating expenses significantly outpaced the quarter’s \(10.6M revenue. Operating cash flow swung from a \)63.7M use to $76.0M generated YTD.
Liquidity and Capital Structure: Total cash reserves decreased substantially to $84.1M as of Sep
...